Fang Zhongbiao, Lyu Jingting, Li Jianhua, Li Chaonan, Zhang Yuxuan, Guo Yikai, Wang Ying, Zhang Yanjun, Chen Keda
Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Front Bioeng Biotechnol. 2022 Aug 9;10:921755. doi: 10.3389/fbioe.2022.921755. eCollection 2022.
Bioreactors are widely used in cell culture-based viral vaccine production, especially during the coronavirus disease 2019 (COVID-19) pandemic. In this context, the development and application of bioreactors can provide more efficient and cost-effective vaccine production to meet the global vaccine demand. The production of viral vaccines is inseparable from the development of upstream biological processes. In particular, exploration at the laboratory-scale is urgently required for further development. Therefore, it is necessary to evaluate the existing upstream biological processes, to enable the selection of pilot-scale conditions for academic and industrial scientists to maximize the yield and quality of vaccine development and production. Reviewing methods for optimizing the upstream process of virus vaccine production, this review discusses the bioreactor concepts, significant parameters and operational strategies related to large-scale amplification of virus. On this basis, a comprehensive analysis and evaluation of the various process optimization methods for the production of various viruses (SARS-CoV-2, Influenza virus, Tropical virus, Enterovirus, Rabies virus) in bioreactors is presented. Meanwhile, the types of viral vaccines are briefly introduced, and the established animal cell lines for vaccine production are described. In addition, it is emphasized that the co-development of bioreactor and computational biology is urgently needed to meet the challenges posed by the differences in upstream production scales between the laboratory and industry.
生物反应器广泛应用于基于细胞培养的病毒疫苗生产,尤其是在2019冠状病毒病(COVID-19)大流行期间。在此背景下,生物反应器的开发和应用能够提供更高效且具成本效益的疫苗生产,以满足全球疫苗需求。病毒疫苗的生产离不开上游生物工艺的发展。特别是,迫切需要在实验室规模进行探索以实现进一步发展。因此,有必要评估现有的上游生物工艺,以便为学术和工业科学家选择中试规模条件,从而最大化疫苗开发和生产的产量及质量。本综述回顾了优化病毒疫苗生产上游工艺的方法,讨论了与病毒大规模扩增相关的生物反应器概念、重要参数和操作策略。在此基础上,对生物反应器中各种病毒(严重急性呼吸综合征冠状病毒2型、流感病毒、热带病毒、肠道病毒、狂犬病病毒)生产的各种工艺优化方法进行了全面分析和评估。同时,简要介绍了病毒疫苗的类型,并描述了已确立的用于疫苗生产的动物细胞系。此外,强调了迫切需要生物反应器与计算生物学共同发展,以应对实验室和工业上游生产规模差异带来的挑战。